AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions
AEON Biopharma, Inc. Class A (AEON)
Company Research
Source: GlobeNewswire
- AEON confirmed that earlier today it held its BPD Type 2a Meeting with the FDA, in line with prior guidance, and is now awaiting official meeting minutes - - Separately, AEON shareholders today voted in favor of the proposals required to complete the transactions announced in November, including the consummation of the PIPE financing and the related Daewoong note exchange - IRVINE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company seeking accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA), today reported on two separate positive events for the Company: AEON confirmed that earlier today it held its scheduled BPD Type 2a meeting with FDA, in line with prior guidance. The Company looks forward to commenting on the meeting’s substance and outcome following receipt of the official meeting minutes from the U.S. F
Show less
Read more
Impact Snapshot
Event Time:
AEON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AEON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AEON alerts
High impacting AEON Biopharma, Inc. Class A news events
Weekly update
A roundup of the hottest topics
AEON
News
- AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711GlobeNewswire
- AEON Biopharma Announces Execution of Exchange Agreement with DaewoongGlobeNewswire
- AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting SchedulingGlobeNewswire
- AEON Biopharma (NASDAQ:AEON) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.MarketBeat
- AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued GrowthGlobeNewswire
AEON
Analyst Actions
- 11/18/25 - HC Wainwright
AEON
Sec Filings
- 1/29/26 - Form 3
- 1/29/26 - Form SCHEDULE
- 1/29/26 - Form SCHEDULE
- AEON's page on the SEC website